China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has entered into a licensing agreement with UK pharmaceutical giant GSK (NYSE: GSK), granting GSK development, manufacturing, and commercialization rights to its pipeline antibody drug conjugate (ADC) HS-20089 for all global territories outside Greater China.
HS-20089: Targeting B7-H4 in Oncology
HS-20089 is an innovative ADC targeting B7-H4, a transmembrane glycoprotein in the B7 superfamily that is highly expressed in various cancers, including ovarian and endometrial cancers. Engineered to deliver a topoisomerase inhibitor (TOPOi) payload, HS-20089 is currently in a Phase I clinical study in China for advanced solid tumors.
Deal Terms and Financial Commitment
Under the terms of the agreement, GSK will pay Hansoh an upfront fee of USD 85 million and is committed to up to USD 1.485 billion in milestone payments, alongside tiered royalties on any future net global sales. This significant financial commitment underscores GSK’s confidence in the potential of HS-20089 to address unmet medical needs in oncology.-Fineline Info & Tech
